<DOC>
	<DOCNO>NCT02856867</DOCNO>
	<brief_summary>This prospective , multicenter , randomize , placebo-controlled , triple-blind phase II trial . The randomization 1:1 randomization ( experimental arm : control arm ) . This study enroll patient histologically confirm esophagogastric adenocarcinoma metastatic disease . Patients previous chemotherapy metastatic esophagogastric cancer . Patients receive nintedanib placebo combination mFOLFOX6 ( 5-Fluorouracil 400 mg/m2 bolus day 1 , 5-Fluorouracil 2400 mg/m2 continuous infusion 46 hour start day 1 , Leucovorin 400 mg/m2 day 1 , Oxaliplatin 85 mg/m2 day 1 ) via IV infusion every 2 week ( 14 day ) . Dose modification nintedanib placebo mFOLFOX6 allow . Patients may continue receive protocol therapy long experienced adverse event require permanent discontinuation study medication demonstrate disease progression . The primary objective test hypothesis progression free survival ( PFS ) prolong HER2-negative patient untreated metastatic esophagogastric adenocarcinoma treat nintedanib plus modified FOLFOX6 ( mFOLFOX6 ) compare placebo plus mFOLFOX6 . The analysis perform 124 event PFS observe pooled arm .</brief_summary>
	<brief_title>Nintedanib Plus mFOLFOX6 Previously Untreated Metastatic Esophagogastric Adenocarcinoma ( MEGAN )</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically confirm esophagogastric adenocarcinoma metastatic ( M1 ) disease HER2negative tumor per local assessment ( accord RüschoffCriteria ) Presence least one evaluable lesion per RECIST v1.1 Representative formalin fix , paraffin embed tumor block unstained tissue slide , either primary tumor metastatic lesion , must available histological central review FGFR2 associate oncogenic pathway tumor stroma analyse Age 18 year old ECOG performance status 01 Within 7 day prior treatment start : adequate bone marrow , liver renal function coagulation parameter : Neutrophils ≥ 1.5 x 109/L Hemoglobin ≥ 9 g/dL ( ≥ 5.6 mmol/L ) . Blood transfusion administration hematopoietic growth factor allow achieve baseline value Platelets ≥ 100 x 109/L . Platelet transfusion administration hematopoietic growth factor allow achieve baseline value Bilirubin ≤ 1.5 x ULN Patients Gilbert syndrome and/or bilirubin &lt; 2 ULN normal AST/ALT eligible SGPT/ALT SGOT/AST ≤ 2.5 x ULN patient liver metastasis SGPT/ALT SGOT/ AST ≤ 1.5x ULN patient without liver metastasis Serum creatinine ≤ 1.5 x ULN creatinine clearance/eGFR &gt; 45 ml/min assess per local standard method No proteinuria CTCAE grade 2 great International normalized ratio ( INR ) &lt; 2 , prothrombin Prothrombin time ( PT ) partial thromboplastin time ( PTT ) &gt; 50 % institutional ULN . No Child Pugh B C hepatic impairment Women childbearing potential ( WOCP ) : define sexually mature woman 1 ) undergone hysterectomy bilateral oophorectomy 2 ) naturally postmenopausal ( amenorrhoea follow cancer therapy rule childbearing potential ) least 12 consecutive month ( i.e . menses time precede 12 consecutive month ) , must : Have negative serum pregnancy test within 7 day prior randomization . Agree remain sexually abstinent , partner sterile ( i.e. , vasectomy ) , use two medically effective method contraception dose 90 day last study treatment . An effective method combination follow ( a+b ) : a. Hormonal method eg , birth control pills ; b . Placement intrauterine device ( IUD ) intrauterine system ( fUS ) , barrier method contraception : condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/ gel/film/ cream/vaginal suppository . This requirement follow screen 24 week last study treatment . During treatment : Patient agree urine pregnancy test perform treatment ; Agree discontinue treatment case pregnancy positive pregnancy test . Female subject breast feed discontinue nursing prior first dose study treatment 6 month last study treatment . Sexually active male participant must use barrier method contraception ( e.g. , condom ) . Before patient registration/randomization , write informed consent must obtain accord International Council Harmonisation/Good Clinical Practice ( ICH/GCP ) national/local regulation . Previous chemotherapy metastatic esophagogastric cancer ( Neoadjuvant adjuvant systemic treatment finish least ( ≥ ) 6 month study inclusion ) History clinical evidence central nervous system metastasis leptomeningeal tumor spread . Other malignant disease previous 5 year ( apart basalcell cancer skin preinvasive cervical cancer ) . Other anticancer therapy ( systemic therapy , radiotherapy , surgery ) within 28 day prior treatment start protocol treatment . Treatment another investigational agent within 28 day prior treatment start protocol treatment . Chronic diarrhea short bowel syndrome Legal incapacity limit legal capacity Known hypersensitivity nintedanib Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration/randomization trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>